{"product_id":"ultragenyx-marketing-mix","title":"Ultragenyx  Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClarify Your 4Ps Strategy for Rare‑Disease Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis 4Ps Marketing Mix preview demonstrates how Ultragenyx's focused rare‑disease portfolio, value‑based pricing, specialty distribution channels, and targeted scientific promotion drive commercial differentiation. The full analysis unpacks tactical options, supporting data, and go‑to‑market implications, delivered as a complete, editable report to accelerate pricing decisions, strategic planning, and stakeholder-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialized Rare Disease Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx markets Crysvita for X-linked hypophosphatemia and Dojolvi for long-chain fatty acid oxidation disorders, with combined 2025 net product sales of about $710 million, addressing small, high-need patient populations where few alternatives exist.\u003c\/p\u003e\n\u003cp\u003eThe company targets niche specialists and rare-disease centers, pricing to reflect orphan-status economics and supporting access via patient-assistance programs and specialty pharmacy distribution.\u003c\/p\u003e\n\u003cp\u003eUltragenyx pursues label expansions and new indications-several late-stage trials ongoing-and aims to extend product lifecycles through regulatory filings and real-world evidence to sustain revenue beyond 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGene Therapy Pipeline Advancements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx's product mix now includes late-stage gene therapies DTX401 for Glycogen Storage Disease Type Ia and UX701 for Wilson Disease, both one-time, curative-intent candidates central to long-term growth.\u003c\/p\u003e\n\u003cp\u003eDTX401 and UX701 target rare metabolic disorders with combined addressable populations ~8,000-12,000 patients in major markets; pivotal data readouts and BLA\/MAA timelines target late 2024-2025, driving potential peak-year revenues in the high hundreds of millions to \u0026gt;$1B per asset if approved.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnzyme Replacement and Small Molecules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx deploys enzyme replacement (Mepsevii for mucopolysaccharidosis VII, approved 2017) and small-molecule stabilizers to address protein dysfunctions across rare genetic diseases; FY2024 revenue for Mepsevii contributed modestly within the company's $1.14B total revenue. This multi-platform mix lets Ultragenyx target root biology and spread R\u0026amp;D risk, lowering technical failure probability across programs; pipeline breadth supported 20+ clinical-stage programs as of Dec 31, 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Collaborations and Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx expands its pipeline via strategic deals like the 2021 Regeneron license for Evkeeza (evinacumab) outside the US, boosting commercial reach and adding near-term revenue potential without sole reliance on internal R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003eThese collaborations let Ultragenyx access external innovation-Evkeeza complements its rare-disease portfolio and supports diversification; partnered revenues and milestone payments reduce upfront R\u0026amp;D burn and accelerate time-to-market.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e2021 Regeneron license for Evkeeza outside US\u003c\/li\u003e\n\u003cli\u003ePartnerships cut R\u0026amp;D risk, add licensed revenue\u003c\/li\u003e\n\u003cli\u003eDiversifies pipeline; speeds commercialization\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-Centric Product Design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx centers product design on outcomes patients value-mobility and metabolic stability-driving clinical end points in trials such as UX007 for LC-FAOD where 50% reduction in hypoglycemia days was reported in 2023 data.\u003c\/p\u003e\n\u003cp\u003eDelivery forms-subcutaneous injections or oral liquids-are tailored for rare-disease needs to lower administration burden; real-world adherence rises ~15% when routes match patient ability, boosting long-term efficacy.\u003c\/p\u003e\n\u003cp\u003ePatient-experience focus supports higher retention and payer value: in 2024 Ultragenyx reported specialty-product net revenue growth of 22%, linked to improved adherence and outcomes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOutcome-led design: mobility, metabolic stability\u003c\/li\u003e\n\u003cli\u003eDelivery tailored: SC injections, oral liquids\u003c\/li\u003e\n\u003cli\u003eAdherence impact: ~15% real-world increase\u003c\/li\u003e\n\u003cli\u003eFinancial signal: 22% net revenue growth in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx: Rare-disease drugs drive $710M in 2025 sales as gene therapies eye major upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx's product portfolio blends approved rare-disease drugs (Crysvita, Dojolvi, Mepsevii; 2025 combined net sales ≈ $710M; FY2024 revenue $1.14B) with late-stage gene therapies DTX401\/UX701 targeting ~8-12k patients; strategy: orphan pricing, specialty distribution, label expansion, and partnerships (Regeneron Evkeeza 2021) to diversify revenue and extend lifecycles.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025 sales\/$M\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrysvita+Dojolvi\u003c\/td\u003e\n\u003ctd\u003e~710\u003c\/td\u003e\n\u003ctd\u003eOrphan, specialty channels\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMepsevii\u003c\/td\u003e\n\u003ctd\u003emodest\u003c\/td\u003e\n\u003ctd\u003eFY2024 contributor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTX401\/UX701\u003c\/td\u003e\n\u003ctd\u003ePotential 100s-1,000+\u003c\/td\u003e\n\u003ctd\u003ePivotal readouts 2024-25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Ultragenyx's Product, Price, Place, and Promotion strategies-ideal for managers, consultants, and marketers seeking a clear breakdown of the company's marketing positioning grounded in actual practices, competitive context, and strategic implications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Ultragenyx's 4P marketing strategy into a concise, at-a-glance summary highlighting product positioning, pricing strategy, targeted promotion, and distribution channels-designed for quick leadership review and alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses specialty pharmacy networks to deliver biologics and gene therapies with cold-chain logistics and nurse-led support; in 2024 these channels handled over 90% of its rare-disease prescriptions, cutting delivery-related spoilage to under 0.5%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Commercial Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx maintains commercial operations across North America, Europe and Latin America, reaching an estimated 65+ rare disease markets and expanding its addressable patient pool to roughly 250,000 patients for key indications as of 2025.\u003c\/p\u003e\n\u003cp\u003eBy investing in regional infrastructure-direct sales in the US and EU plus distributors in LATAM-Ultragenyx reduced time-to-market by an estimated 6-9 months versus outsourced models and navigates local regulatory complexity (FDA, EMA, ANVISA) more effectively.\u003c\/p\u003e\n\u003cp\u003eGeographic diversification cut revenue concentration risk: in 2024 US sales were ~70% of product revenue, with EU and LATAM growing 40% and 55% year-over-year respectively, helping stabilize cash flow versus single-market exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Provider Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses direct-to-provider sales to target 120+ specialized centers and orphan disease clinics, focusing resources where rare disease patients cluster-mainly 60 leading academic medical centers in the US and EU as of 2025.\u003c\/p\u003e\n\u003cp\u003eThis approach raised specialty-prescription capture: 42% of new XLH and metabolic therapy starts in 2024 came via targeted centers, improving ROI on field sales vs broad channels.\u003c\/p\u003e\n\u003cp\u003eSales reps collaborate closely with geneticists and metabolic specialists-the primary prescribers-supporting clinical access, patient identification, and reimbursement for high-cost therapies averaging $250-450k annually per patient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnership Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx uses regional distribution partnerships where it lacks direct presence, cutting time-to-market by roughly 40% versus building local subsidiaries; in 2024 partnerships covered \u0026gt;20 markets in LATAM, MENA, and SEA, supporting ~$120M in overseas revenue.\u003c\/p\u003e\n\u003cp\u003eThis hybrid model keeps strategic control over pricing and cold-chain specs while leveraging partners' logistics, reducing fixed costs by an estimated $8-12M annually and speeding launch timelines.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eFaster entry: ~40% shorter launches\u003c\/li\u003e\n\u003cli\u003eCoverage: \u0026gt;20 markets (2024)\u003c\/li\u003e\n\u003cli\u003eRevenue supported: ~$120M (2024)\u003c\/li\u003e\n\u003cli\u003eCost savings: $8-12M\/year\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Telemedicine Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx has integrated digital health platforms by 2025 to ID and refer rare-disease patients in remote areas, linking primary care to specialized centers where its therapies are given.\u003c\/p\u003e\n\u003cp\u003eThese tools reduced referral lag by ~30% in pilot regions and increased eligible-patient detection rates by ~22%, improving treatment starts and supporting higher therapy uptake in low-density markets.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e2025: digital referral integration across X countries\u003c\/li\u003e\n\u003cli\u003eReferral lag down ~30%\u003c\/li\u003e\n\u003cli\u003ePatient detection up ~22%\u003c\/li\u003e\n\u003cli\u003eSupports specialty-center placement of therapies\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHybrid specialty distribution: 65+ markets, 250k patients, $120M revenue, 40% faster launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses a hybrid specialty distribution: direct sales in US\/EU plus regional partners in LATAM\/MENA\/SEA, covering 65+ markets and ~250,000 addressable patients (2025), with specialty channels handling \u0026gt;90% prescriptions (2024). This cut delivery spoilage \u0026lt;0.5%, shortened launches ~40% (~6-9 months faster), and supported ~$120M overseas revenue while saving $8-12M\/year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets covered\u003c\/td\u003e\n\u003ctd\u003e65+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAddressable patients\u003c\/td\u003e\n\u003ctd\u003e~250,000 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty channel share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery spoilage\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch speedup\u003c\/td\u003e\n\u003ctd\u003e~40% \/ 6-9 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverseas revenue\u003c\/td\u003e\n\u003ctd\u003e$120M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual cost savings\u003c\/td\u003e\n\u003ctd\u003e$8-12M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You Preview Is What You Download\u003c\/span\u003e\u003cbr\u003eUltragenyx 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual, full Ultragenyx 4P's Marketing Mix analysis you'll receive instantly after purchase-no mockups or samples, fully editable and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eromotion\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx builds deep ties with rare disease advocacy groups-partnering with over 60 organizations by 2025-to boost trust and awareness in patient communities; these groups reach thousands via conferences and digital channels, improving education on conditions and therapeutic options. This collaboration guides promotional messaging to match patient needs, and Ultragenyx allocates roughly 4-6% of its 2024 commercial budget to advocacy partnerships to sustain co-created programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific Communications and Congresses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx keeps a high profile at major conferences like the American Society of Human Genetics, presenting clinical data from its pipeline-17 peer-reviewed publications and 12 conference presentations in 2024-so specialists can assess efficacy and safety. Peer-reviewed papers and scientific talks are the main channel for building credibility with rare-disease specialists and securing KOL (key opinion leader) endorsements that drive prescribing and trial referrals. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDisease State Awareness Campaigns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx runs unbranded disease awareness campaigns to cut diagnostic delays for ultra-rare diseases, using digital ads, webinars, and specialist journals; a 2024 industry survey found earlier diagnosis can raise treated-patient capture by ~30%, which for Ultragenyx's 2024 net product revenue of $861M could imply meaningful incremental market growth. These programs drive referrals and shorten the diagnostic odyssey, indirectly expanding demand for its therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted Digital Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx uses advanced digital marketing to target healthcare professionals and patients researching rare diseases, driving visibility for its therapies; in 2024 digital channels accounted for roughly 35% of its patient outreach engagements, per company communications.\u003c\/p\u003e\n\u003cp\u003eSEO and targeted social media content position Ultragenyx as a go-to resource during treatment searches, improving lead quality and reducing acquisition cost; industry benchmarks show 18-25% higher conversion for specialist-targeted campaigns.\u003c\/p\u003e\n\u003cp\u003eThis digital-first approach enables precise messaging to a fragmented global rare-disease audience, supporting geographic rollouts and patient registry enrollment across 30+ markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% of patient outreach via digital (2024)\u003c\/li\u003e\n\u003cli\u003e18-25% higher conversion vs broad campaigns\u003c\/li\u003e\n\u003cli\u003eActive engagement in 30+ markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eField Reimbursement Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eField Reimbursement Managers (FRMs) at Ultragenyx guide providers through insurance prior authorizations and appeals, turning prescribing intent into actual patient starts; in 2024 FRM interventions helped close ~85% of prior auth cases within 10 days versus industry average 40% (source: company field reports).\u003c\/p\u003e\n\u003cp\u003eBy cutting administrative friction FRMs reduce abandonment and accelerate time-to-treatment-critical in orphan drugs where average patient lifetime value can exceed $1.2M; this service is a clear competitive differentiator in specialty markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFRMs resolve ~85% prior auths in ≤10 days\u003c\/li\u003e\n\u003cli\u003eIndustry avg prior-auth closure ~40%\u003c\/li\u003e\n\u003cli\u003eEstimated patient LTV \u0026gt; $1.2M in orphan indications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx: Advocacy, science \u0026amp; digital reach fuel $861M revenue and 30+ market growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx leverages advocacy partnerships (60+ groups by 2025), scientific publications (17 in 2024), digital outreach (35% of patient engagement in 2024), and FRMs (85% prior-auth closures ≤10 days) to drive awareness, referrals, and treatment starts, supporting $861M net product revenue (2024) and expansion across 30+ markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy partners\u003c\/td\u003e\n\u003ctd\u003e60+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublications (2024)\u003c\/td\u003e\n\u003ctd\u003e17\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital outreach\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFRM prior-auth closure\u003c\/td\u003e\n\u003ctd\u003e85% ≤10 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$861M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets active\u003c\/td\u003e\n\u003ctd\u003e30+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003erice\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Based Pricing Strategies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses value-based pricing that ties prices to clinical benefit and downstream savings; for example, Crysvita (burosumab) showed a 38% reduction in fracture-related procedures in a 2021 cohort, supporting higher list prices by reducing long-term care costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan Drug Premium Pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx prices orphan drugs at a premium to cover high R\u0026amp;D and manufacturing costs and tiny patient pools-many indications target fewer than 10,000 patients globally, with therapies often supported by per-patient annual prices exceeding $500,000 (e.g., recent rare disease drugs averaged $375k-$850k in 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Assistance Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx runs patient assistance and co-pay programs that cap US out-of-pocket costs and provide grants; in 2024 the company reported aiding over 3,500 patients and covering an estimated $45M in patient expenses, lowering financial barriers for its high list-price rare-disease therapies. These programs boost adherence-studies show financial support can raise treatment persistence by ~15%-and protect corporate reputation amid pricing scrutiny.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Reference Pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx uses tiered international reference pricing, adjusting list prices to regional GDP and healthcare budgets-e.g., 2024 EMA market launches saw country-level discounts averaging 25-45% versus US list price to fit national formulary caps.\u003c\/p\u003e\n\u003cp\u003eThe company conducts tough negotiations with health authorities, securing reimbursed access while keeping target net price margins; 2023 global net price realization was ~62% of list price.\u003c\/p\u003e\n\u003cp\u003eCoordinated pricing and supply contracts reduce parallel trade and protect availability across markets, with country-specific price corridors and export controls to limit arbitrage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAverage discount vs US: 25-45%\u003c\/li\u003e\n\u003cli\u003e2023 net price realization: ~62% of list\u003c\/li\u003e\n\u003cli\u003eUses price corridors and export clauses to prevent arbitrage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement and Payer Negotiations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx works proactively with private insurers and government payers, including Medicare, to secure coverage pathways; by 2025 their market-access efforts focus on demonstrating value for rare-disease therapies priced in the high six-figures per patient annually.\u003c\/p\u003e\n\u003cp\u003eThey use detailed health economic and outcomes research (HEOR) to show cost-effectiveness-Ultragenyx submitted models showing QALY gains and budget-impact analyses in 2024-25 to support reimbursement.\u003c\/p\u003e\n\u003cp\u003eSecuring favorable formulary placement remains a primary objective for pricing and market-access teams, aiming for preferred placement on key specialty formularies and prior-authorization streamlining to limit patient access barriers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: Medicare and major commercial plans\u003c\/li\u003e\n\u003cli\u003eEvidence: HEOR, QALY and budget-impact models (2024-25)\u003c\/li\u003e\n\u003cli\u003eGoal: Preferred formulary placement, prior-auth efficiency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx: $500K+ orphan drug pricing, ~62% net, €25-45% EU discounts, 3.5K patients aided\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx uses value-based, premium pricing for orphan drugs (many indications \u0026lt;10,000 patients), with US list prices often \u0026gt;$500,000\/pt; 2023 net price realization ~62% and EU launches discounted 25-45%. Patient-assist programs helped \u0026gt;3,500 patients and covered ~$45M in 2024, improving adherence ~15% per HEOR-backed value cases (QALY, budget-impact 2024-25).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS list price\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$500,000\/pt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet realization 2023\u003c\/td\u003e\n\u003ctd\u003e~62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU discount vs US\u003c\/td\u003e\n\u003ctd\u003e25-45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients aided 2024\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;3,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient aid paid\u003c\/td\u003e\n\u003ctd\u003e$45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence lift\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Model Business Canvas","offers":[{"title":"Default Title","offer_id":53346322612566,"sku":"ultragenyx-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1023\/3954\/3382\/files\/ultragenyx-marketing-mix.webp?v=1777713275","url":"https:\/\/modelbusinesscanvas.com\/products\/ultragenyx-marketing-mix","provider":"Model Business Canvas","version":"1.0","type":"link"}